Vertex has begun a full-court press for Journavx, enlisting NBA All-Star Jayson Tatum to discuss his use of the new ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...

Discover why Vertex Pharmaceuticals earns a 'Buy' rating with strong CF drug sales, high margins, and new gene therapy deals. Click here to read more.

The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vertex also announced enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of ...

As the Chicago Blackhawks prepare to celebrate a century of history and championships, the organization is grappling with a more pressing concern... its future. A franchise that dominated the 2010s, ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex ...